Stocks that have been under pressure this week could be primed for a rebound. The major averages rose on Friday, attempting a comeback from the prior session's losses and the Dow Jones Industrial Average's worst day since March 2023. Despite the recovery attempt, all three indexes are tracking for a losing week.
mountain Biogen stock. But analysts also think Biogen is due for a rebound, with 74% polled by FactSet rating the stock either a buy or overweight. Average analyst price targets imply more than 45% upside going forward. Baird analyst Brian P. Skorney recently noted optimism over Biogen's potential expansion in Latin America, where the company can address roughly 2,000 to 4,000 patients for its spinal muscular atrophy treatment Spinraza.